Last updated: July 14, 2026
Agios Pharmaceuticals, Inc. v. Annora Pharma Private Limited (D.N.J. 1:26-cv-00603) is a newly filed Hatch-Waxman-style patent case in 2026. No case merits, asserted patents, or procedural posture are provided in the available record here, so a complete litigation summary (claims, patents-in-suit, venue posture, pleadings timeline, stipulations, or remedies sought) cannot be constructed.
What patents are asserted in Agios v. Annora Pharma in 1:26-cv-00603?
Featured snippet: The asserted patents-in-suit are not stated in the available information, so the patent estate and legal theories cannot be mapped.
Which patent numbers and claims are at issue?
No patent numbers, publication identifiers, or claim numbers are provided.
Who is the plaintiff and who is the accused entity?
Plaintiff: Agios Pharmaceuticals, Inc.
Defendant: Annora Pharma Private Limited.
Complaint number: 1:26-cv-00603.
What is the procedural status of Agios v. Annora Pharma (1:26-cv-00603)?
Featured snippet: The case is filed, but the current stage (motion practice, scheduling order, Markman timing, or stay status) is not provided.
Key docket milestones that are missing
No information is provided on:
- Complaint filing date (exact date)
- Service date
- Answer or responsive pleading deadline
- Rule 12 motion practice
- Scheduling order entry
- Pretrial and Markman dates
- Preliminary injunction motions
Is the case stayed under Hatch-Waxman timing?
No stay information is provided (for example, an FDA approval-trigger stay, a 30-month stay link, or litigation-to-approval coordination).
What is the Hatch-Waxman or Paragraph IV theory in the Agios v. Annora case?
Featured snippet: The specific Orange Book listing, the asserted FDA submission linkage (ANDA/BLA/505(b)(2)), and the Paragraph IV basis are not stated in the available record.
What drug and FDA application are implicated?
No asserted drug name, NDA/ANDA number, or Orange Book tie-in is provided.
What types of infringement are alleged?
No allegations are provided regarding:
- Direct infringement
- Indirect infringement (inducement/contributory)
- Willfulness
- Specific manufacturing or use acts
What generic entry risks exist for Annora Pharma based on Agios v. Annora (1:26-cv-00603)?
Featured snippet: Without the accused product identity and Orange Book patents, launch risk cannot be quantified.
Potential launch triggers that cannot be assessed
- Whether any patents are expiring or already expired
- Whether a 30-month stay is in effect
- Whether settlement terms could trigger a launch date
- Whether design-arounds are implicated
How strong is the patent estate for Agios against Annora in 1:26-cv-00603?
Featured snippet: Strength depends on the patents-in-suit and their claim scope; those are not provided.
Claim-scope and validity analysis not available
A patent strength review requires:
- Patent numbers and key independent claims
- Prior art and prosecution history
- Alleged equivalency/design-around details
- District court posture (claim construction status)
No such details exist in the provided record.
What patent litigation outcomes matter for settlements in Agios v. Annora (1:26-cv-00603)?
Featured snippet: Settlement signals and requested relief are not stated.
What outcomes are missing from the record
- Whether the parties are negotiating a consent judgment or covenant-not-to-sue
- Whether an injunction is sought and against what acts
- Whether any dismissal-with-prejudice or stipulation is filed
- Whether a trial date is set
What is the FDA regulatory status implicated by Agios v. Annora Pharma?
Featured snippet: FDA pathway, approval status, and Orange Book listing status are not provided.
Missing FDA linkage details
- NDA/ANDA/BLA number
- Submission type (ANDA vs 505(b)(2))
- Paragraph IV certification (I-IV) and the listed triggering patents
- Any FDA communications affecting the timeline
How does Agios v. Annora compare with other Agios Hatch-Waxman matters?
Featured snippet: Comparisons require a set of asserted patents and outcomes across cases; the asserted set in this case is not given.
Missing comparators
- Prior suits by Agios against other ANDA filers
- Settlement or non-infringement outcomes
- Common patents-in-suit and recurring defense strategies
What manufacturing or IP barriers could block Annora’s product launch?
Featured snippet: Barriers depend on the accused claims, formulation/manufacturing steps, and the presence of method-of-use or composition-of-matter coverage; none are provided.
Barriers that cannot be mapped
- Process patent constraints
- Formulation constraints (excipients, polymorphs, particle size, release profiles)
- Method-of-use constraints (indication-specific dosing regimens)
- Bioequivalence or stability limitations driven by IP terms
Timeline and docket view for 1:26-cv-00603
Featured snippet: A timeline cannot be populated without docket events.
Inputs not available
- Filing date
- Service date
- Responsive pleading dates
- Motions (TRO, preliminary injunction, Rule 12, summary judgment)
- Claim construction schedule
- Trial or dispositive deadlines
Key Takeaways
- Agios Pharmaceuticals, Inc. v. Annora Pharma Private Limited (1:26-cv-00603) is filed in 2026, but the provided record contains no asserted patents, no accused product identity, and no docket milestones.
- A litigation summary that is actionable for freedom-to-operate, launch risk, or settlement valuation cannot be produced from the available information.
FAQs
- Which patents-in-suit are listed in Agios Pharmaceuticals v. Annora Pharma Private Limited (1:26-cv-00603)?
- What is the accused product and which FDA application is linked to 1:26-cv-00603?
- Is 1:26-cv-00603 stayed under Hatch-Waxman timing or FDA approval milestones?
- Has Agios sought a preliminary injunction or other immediate relief in 1:26-cv-00603?
- Are any settlements or consent judgments disclosed for Agios v. Annora Pharma in 1:26-cv-00603?
References (APA)
- United States District Court for the District of New Jersey. Agios Pharmaceuticals, Inc. v. Annora Pharma Private Limited, No. 1:26-cv-00603.
